FR2838350A1 - L'acide lactique directement dans l'intestin - Google Patents

L'acide lactique directement dans l'intestin Download PDF

Info

Publication number
FR2838350A1
FR2838350A1 FR0204661A FR0204661A FR2838350A1 FR 2838350 A1 FR2838350 A1 FR 2838350A1 FR 0204661 A FR0204661 A FR 0204661A FR 0204661 A FR0204661 A FR 0204661A FR 2838350 A1 FR2838350 A1 FR 2838350A1
Authority
FR
France
Prior art keywords
gastro
lactic acid
constipation
treatment
solid support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0204661A
Other languages
English (en)
Other versions
FR2838350B1 (fr
Inventor
Georges Serge Grimberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0204661A priority Critical patent/FR2838350B1/fr
Publication of FR2838350A1 publication Critical patent/FR2838350A1/fr
Application granted granted Critical
Publication of FR2838350B1 publication Critical patent/FR2838350B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composition gastro-intestinale gastro-résistante composée par de l'acide lactique supporté par un mélange pulvérulent.

Description

i Le lactulose passe dans l'intestin. Sa métabolisation par les bactéries
donne
notamment de l'acide lactique.
Le lactulose est parfaitement connu pour son activité thérapeutique, notamment dans
la constipation et l'encéphalopathie hépatique.
Personne, à ce jour, n'a mis de l'acide lactique directement dans l'intestin. J'ai donc mis dans une gélule 50 mg d'acide lactique. J'ai rendu la gélule gastro résistante et je l'ai donnée à des femmes constipées: très rapidement leurs selles sont
devenues molles et n'ont pas eu de diarrhées.
L'acide lactique est un liquide. Pour le mettre en gélule il faut un support. J'ai choisi du charbon-diméthicone (brevet Carbotic n 97 01410) car il permet une adhésion à
la muqueuse.
Le support peut étre de la boue par exemple, mais il ne faut pas qu'elle ait une
capacité antiacide.
La dose d'acide lactique par gélule peut étre augmentée mais ne peut l'être beaucoup, puisque c'est un liquide. Par contre, la posologie peut facilement doubler
ou tripler la dose, notamment au début de la prescription thérapeutique.

Claims (3)

REVENDICATIONS
1. Composition gastro-intestinale gastro-résistante caractérisée en ce qu'elle contient au moins 50 mg d'acide lactique liquide supporté par un melange pulvérulent charbon/diméthicone ou bien éventuellement supports par de la boue ne
présentant pas d'activité anti-acide.
2. Composition gastro-intestinale selon la revendication n 1 caractérisée en ce
qu'elle peut être mise en gélule qui est rendue gastro-résistante.
3. Composition gastro-intestinale selon la revendication n 1 caractérisée en ce
FR0204661A 2002-04-15 2002-04-15 L'acide lactique directement dans l'intestin Expired - Fee Related FR2838350B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0204661A FR2838350B1 (fr) 2002-04-15 2002-04-15 L'acide lactique directement dans l'intestin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204661A FR2838350B1 (fr) 2002-04-15 2002-04-15 L'acide lactique directement dans l'intestin

Publications (2)

Publication Number Publication Date
FR2838350A1 true FR2838350A1 (fr) 2003-10-17
FR2838350B1 FR2838350B1 (fr) 2005-08-26

Family

ID=28459821

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0204661A Expired - Fee Related FR2838350B1 (fr) 2002-04-15 2002-04-15 L'acide lactique directement dans l'intestin

Country Status (1)

Country Link
FR (1) FR2838350B1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1143685A (fr) * 1955-12-02 1957-10-03 Leurquin Lab Procédé de fabrication de médicaments à action retardée dans le tube digestif
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
FR2390953A1 (fr) * 1977-05-20 1978-12-15 Grimberg Georges Medicament a base de charbon
JPH05255097A (ja) * 1992-01-24 1993-10-05 Miyarisan Seibutsu Igaku Kenkyusho:Kk 液状組成物
FR2759294A1 (fr) * 1997-02-07 1998-08-14 Georges Serge Grimberg Composition oesogastro-intestinale a base de charbon dont les pores sont bouches par un enrobage, et qui peut etre utilisee seule ou en associatioin avec d'autres molecules
WO2000033866A1 (fr) * 1998-12-04 2000-06-15 Provalis Uk Limited Composition pharmaceutique contenant de l'insuline
JP2000327569A (ja) * 1999-05-20 2000-11-28 Nippon Taanaa Kk 腸内環境改善剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1143685A (fr) * 1955-12-02 1957-10-03 Leurquin Lab Procédé de fabrication de médicaments à action retardée dans le tube digestif
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
FR2390953A1 (fr) * 1977-05-20 1978-12-15 Grimberg Georges Medicament a base de charbon
JPH05255097A (ja) * 1992-01-24 1993-10-05 Miyarisan Seibutsu Igaku Kenkyusho:Kk 液状組成物
FR2759294A1 (fr) * 1997-02-07 1998-08-14 Georges Serge Grimberg Composition oesogastro-intestinale a base de charbon dont les pores sont bouches par un enrobage, et qui peut etre utilisee seule ou en associatioin avec d'autres molecules
WO2000033866A1 (fr) * 1998-12-04 2000-06-15 Provalis Uk Limited Composition pharmaceutique contenant de l'insuline
JP2000327569A (ja) * 1999-05-20 2000-11-28 Nippon Taanaa Kk 腸内環境改善剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199344, Derwent World Patents Index; Class B05, AN 1993-348354, XP002242137 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 14 5 March 2001 (2001-03-05) *

Also Published As

Publication number Publication date
FR2838350B1 (fr) 2005-08-26

Similar Documents

Publication Publication Date Title
Hakkarainen et al. Tolfenamic acid is as effective as ergotamine during migraine attacks
Santucci et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha.
CN1241569C (zh) 用于治疗鼻炎/结膜炎的非镇静抗组胺药物与影响白三烯活性物质的新药物并用
JP2005515966A5 (fr)
WO2003065982A3 (fr) Technique d'absorption de composes therapeutiques par l'intermediaire de transporteurs du colon
IL157921A0 (en) Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US20080021021A1 (en) Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist
JP2004075690A (ja) 静脈内注入用アレンドロナート組成物
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
Scavone et al. Enhanced bioavailability of triazolam following sublingual versus oral administration
BR9608435A (pt) Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas.
Ruilope et al. Eprosartan versus enalapril in elderly patients with hypertension: a doubleblind, randomized trial
JPWO2007122812A1 (ja) 炎症性腸疾患治療薬
CN105163743A (zh) 用于治疗幽门螺杆菌的药物组合物
Wilson et al. Intramuscular diclofenac sodium for postoperative analgesia after laparoscopic cholecystectomy: a randomised, controlled trial
Girod et al. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
Passàli et al. Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study
CN103826644A (zh) 口服补液组合物
FR2838350A1 (fr) L'acide lactique directement dans l'intestin
FR2558060A1 (fr) Nouvelles formes pharmaceutiques contenant des diphosphonates
Biller et al. Tetracycline-induced esophagitis in adolescent patients
Ferrer-Dufol et al. Fatal serotonin syndrome caused by moclobemide-clomipramine overdose
CN103263415A (zh) 注射用左旋泮托拉唑钠组合物及其制备方法

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091231